))
…
continue reading
1
Bioactive Components of Human Milk Including HMOs and Other Prebiotics
Annenberg Center for Health Sciences
Human breast milk is comprised of several bioactive components, including human milk oligosaccharides (HMOs), which are non-nutritive carbohydrates unique to human milk. In this course, Lars Bode, PhD, introduces HMOs and describes the structure, composition, and infant health benefits of these compounds. Topics include the prebiotic effects of HMOs, particularly related to the gastrointestinal and immune systems, but also growth and development and allergies. Also reviewed are the oligosacc ...
…
continue reading
Presented by Lars Bode, PhD Human breast milk is comprised of several bioactive components, including human milk oligosaccharides (HMOs), which are non-nutritive carbohydrates unique to human milk. In this course, Lars Bode, PhD, introduces HMOs and describes the structure, composition, and infant health benefits of these compounds. Topics include …
…
continue reading
Harry is a 72-year-old with diabetes and hypertension but no primary event with LDL-C 110 mg/dL and 1-year ASCVD risk score of 43%. Although he is a candidate for high-intensity statin therapy, atorvastatin 10 mg daily is the highest dose he tolerates.Di Annenberg Center for Health Sciences
…
continue reading
Anisa is a 54-year-old with hypertension and stage 3 chronic kidney disease (but not diabetes mellitus) and LDL-C <190 mg/dL despite high-intensity statin therapy. Results of clinical trials show that reducing atherogenic lipoproteins to very low levels (LDL-C <50 mg/dL) is beneficial in reducing the risk of a cardiovascular event compared to highe…
…
continue reading
Jessica is a 24-year-old with heterozygous familial hypercholesterolemia with LDL-C hyperlipidemia despite high-intensity statin therapy. The benefits and limitations of the addition of ezetimibe or a PCSK9 inhibitor are discussed.Di Annenberg Center for Health Sciences
…
continue reading
Mateo is a 68-year-old male treated with moderate-intensity statin therapy who needs treatment intensification for secondary prevention. Treatment options are discussed based on clinical trials such as IMPROVE-IT, ODYSSEY Long Term, FOURIER, and GLAGOV.Di Annenberg Center for Health Sciences
…
continue reading
Patients who receive a prescription for statin therapy often remain at increased cardiovascular risk due to elevated low-density lipoprotein cholesterol (LDL-C). Organizations such as the American College of Cardiology, American Heart Association, and National Lipid Association have developed algorithms to guide the management of patients with LDL-…
…
continue reading
